The Becker Muscular Dystrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Becker Muscular Dystrophy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Becker Muscular Dystrophy by ten companies/universities/institutes. The top development phase for Becker Muscular Dystrophy is preclinical with three drugs in that stage. The Becker Muscular Dystrophy pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Becker Muscular Dystrophy pipeline products market are: Sarcomatrix Therapeutics, MLAB Biosciences and SOM Biotech.
The key targets in the Becker Muscular Dystrophy pipeline products market include Integrin Alpha 7, Integrin Beta 1, and Histone Deacetylase 2.
The key mechanisms of action in the Becker Muscular Dystrophy pipeline product include Integrin Alpha 7 Agonist with two drugs in Discovery. The Becker Muscular Dystrophy pipeline products include five routes of administration with the top ROA being Oral and four key molecule types in the Becker Muscular Dystrophy pipeline products market including Small Molecule, and Synthetic Peptide.
Becker Muscular Dystrophy overview
Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation; difficulty with running, hopping, and jumping; toe walking; breathing problems; cognitive problems; and frequent falls.
For a complete picture of Becker Muscular Dystrophy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
